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Serum proteome changes and accelerated reduction of fat mass after 
Laparoscopic Gastric Plication in morbidly obese patients   
 
Abstract 
Laparoscopic Gastric Plication (LGP) is a relatively new bariatric surgical procedure which no 
part of the stomach is removed. It is not clearly understood how LGP leads to fatty tissue 
reduction. We aimed to investigate the impact of LGP on serum proteome and understand 
molecular mechanisms of LGP-induced weight loss post-surgery. A Prospective observational 
study of 16 obese individuals who underwent LGP was performed. A Label-free quantitative 
shotgun proteomics approach was used to compare serum proteome of subjects before surgery 
with serum of the same individuals 1 to 2 months post-surgery (T1) and 4 to 5 months post-
surgery (T2). The proteome analysis revealed that 48 proteins were differentially regulated 
between pre-surgery and T1, and seven proteins between pre-surgery and T2 of which six 
proteins were shared between the two timepoints. Among differentially regulated proteins, four 
proteins (SRGN, FETUB, LCP1 and CFP) have not previously been described in the context of 
BMI/weight loss. Despite few differences following LGP, most regulated serum proteins are in 
accordance with alternative weight loss procedures. Pathway analysis revealed changes to lipid- 
and inflammatory pathways, including PPARα/RXRα, LXR/RXR and FXR/RXR activation, 
especially at T1. At T2, the pathways related to inflammation and immune system are most 
affected.  
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Significance 
Among the available clinical therapies for morbid obesity, bariatric surgery is considered as the 
most effective approach to achieve long-term weight loss, alongside a significant improvement 
in metabolic syndrome. However, very little is known about the underlying mechanism 
associated with significant weight loss post-surgery. Understanding such mechanisms could lead 
to development of safer non-surgical weight loss approaches. We here present the first analysis 
of the impact of LGP on the serum proteome, to bring new insights into the underlying molecular 
mechanism. Our findings indicate that LGP has a comprehensive systemic effect based on the 
blood serum proteome profile which might account for accelerated reduction of fat mass after 
surgery, thus, food restriction is not the only reason for weight loss following this unique 
surgical approach. As secretory regions of the stomach are preserved in LGP and it is associated 
with minimal physiological and anatomical changes, the findings are of high importance in the 
field of bariatric surgery and weight loss. 
Keywords Bariatric surgery; Laparoscopic Gastric Plication; Label free quantitation; Obesity; 
Proteomics 
Introduction 
The global prevalence of obesity has almost tripled since 1975 and has had an impact of 
$2.0 trillion for the worldwide economy [1-2].  Obesity is accompanied by systemic chronic low-
grade inflammation, which may result in obesity-related comorbidities, such as type 2 diabetes 
and cardiovascular diseases [3]. Considering its growing prevalence and related medical 
problems, the necessity for successful treatments has been increased.  
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Bariatric surgery is the most effective treatment option for sustainable weight loss and 
improvement in comorbidities for morbidly obese individuals [4]. Roux-en-Y gastric bypass 
(RYGB) and laparoscopic sleeve gastrectomy (LSG) are the most common techniques. However, 
both suffer from complications in the form of staple line leakage or bleeding, which mainly arise 
from cutting the edge of the stomach [5].  
By contrast, gastric plication (GP) with laparoscopic modification (LGP) reduces gastric 
volume by plication of the greater curvature of the stomach, that is without surgical removal of a 
part of the stomach which, to a large extent, mitigates complications. It was first described by 
Tretbar et al. 1976 in an animal study [6], and expanded with the laparoscopic modification by 
Talebpour and Amoli 2007 in a human study [7]. LGP is reversible, the gastric fundus is 
preserved, it is without foreign body placement and it is associated with minimal risk of nutrient 
deficiency, the common complication after RYGB [8-10]. Additionally, most of the weight loss 
following LGP is attributed to a loss of body fat mass with minimal fat-free mass reduction. 
Accordingly, it fulfills the ideal objective of any weight loss surgery in terms of body 
composition changes [11]. For all these reasons, LGP is an attractive alternative bariatric 
technique that is gaining increased usage [8]. In some reports, its complications and its effect on 
weight loss, on patient metabolic profile and on some selected gut hormones have been 
investigated [12-14]. However, as a relatively new technique, few studies have compared LGP 
with other well-established methods [8]. Therefore, it is still considered an investigational 
procedure.  
It is now evident that food restriction is not the only reason for losing weight and 
improvements in obesity-related comorbidities after bariatric surgeries. It is of great importance 
to elucidate the underlying mechanism associated with significant weight loss post-surgery.  
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Previously, serum lipidomics in gastric bypass and banding were studied. It has been suggested 
that metabolic improvement after RYGB may be due to lipid profile alterations [15].  
Given the lack of studies investigating the molecular systemic impact of LGP and 
bariatric surgery, we aimed to elucidate the systemic effects of this relatively new procedure on 
the molecular level, represented by the serum proteome. Blood serum bathes the internal organs 
and, as such, allows for studying the systemic impact of system perturbation [16]. Our 
hypothesis was that the effects of LGP, without gastric resection or bypass, extend beyond 
limitations in food intake due to restrictions of gastric volume. LGP, in contrast to LSG or 
RYGB, is associated with minimal physiological and anatomical changes [17-18], hence, 
studying the proteome profile changes could be informative.  
To this end, we describe the systemic impact of LGP on the global serum proteome 
changes pre-surgery, using a label-free quantitative proteomics strategy, by comparing pre-
surgery samples with 1 to 2 months post-surgery (T1) and 4 to 5 months post-surgery (T2). The 
present study provides deeper insight into systemic effects of LGP and its underlying molecular 
mechanism. 
Materials and Methods 
Study cohort and serum samples 
A total of 16 obese subjects undergoing LGP by the same surgeon between November 
2015 until May 2016 was consecutively recruited for this prospective observational study. The 
two-row LGP procedure was performed [17]. Subjects fulfilled the inclusion criteria if they were 
aged above 18 years with BMI>40 kg/m2 or >35 kg/m2 with at least one obesity-related 
comorbidity or >30 kg/m2 with metabolic syndrome. The exclusion criteria were as follows: any 
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psychological condition that could affect decision-making capabilities of the subjects (as defined 
by a psychiatrist), alcohol or drug abuse, uncontrolled malignant disease, and heart, renal or 
hepatic failure. All subjects were evaluated by a psychiatrist, an endocrinologist, a cardiologist, 
and a nutritionist before the surgical procedure. Before LGP, there was not any special diet for 
the subjects. After LGP, they took liquids (nutrient rich formulation) for 14 days, semi-liquids 
for 14 days, soft foods for 14 days and after that, normal foods with 800 kcal per day. Written 
consent was obtained and the study approved by the local ethical authorities.  
Whole blood samples were collected after overnight fasting at three timepoints: pre-
surgery, 1 to 2 months post-surgery (T1) and 4 to 5 months post-surgery (T2). It should be noted 
that seven subjects were excluded from analysis due to their unavailability at T2. Blood 
collection tubes were incubated at room temperature for 40 min, then centrifuged at 3000g for 10 
min at 4°C. The serum was collected and stored in aliquots at -80°C. 
Proteomics-sample preparation 
Initially, all samples were randomized. Serum samples were depleted of the six most 
abundant proteins (albumin, IgG, IgA, antitrypsin, transferrin and haptoglobin) using the Agilent 
Multiple Affinity Removal column (4.6×50 mm) according to the manufacturer’s instructions 
(Agilent Technologies, CA, USA). Filter-aided sample preparation protein digestion protocol 
was used to prepare samples for LC-MS [19-20]. The protein concentrations were measured with 
absorbance at 280nm (A280) using a NanoDrop 1000 UV−vis spectrophotometer (Thermo 
Scientific, Waltham, USA). 200µg of samples were transferred to YM-10 kDa spin filter 
(Millipore, Billerica, USA) and centrifuged at 14000g for 15 min at 4°C. A 400µl digestion 
buffer (0.5% sodium deoxycholate in 50mM triethylammonium bicarbonate) was added. Proteins 
were reduced with 10mM Tris (2-Carboxyethyl) phosphine and alkylated with 50mM 
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chloroacetamide for 20 min at 37°C. Samples were centrifuged at 14000g, 400µl of digestion 
buffer was added, followed by centrifugation. Protein digestion was carried out with 2µg 
sequencing-grade-modified trypsin (Promega, Madison, USA) diluted in 50µL digestion buffer 
and followed by overnight incubation at 37°C. The peptide material was recovered by 
centrifugation followed by phase separation, by adding 3:1 (v/v) ethyl acetate: sample volume 
and acidified with formic acid (FA) to a concentration of 1%. The tube was vortexed and 
centrifuged at 14000g for 1 min. The peptide-rich aqueous phase was collected, dried in a 
vacuum centrifuge, and stored at -80°C.  
LC-MS/MS sample analysis 
Prior to LC-MS/MS analysis, the peptides were resuspended in 2% acetonitrile, 0.1% FA 
and 0.1% trifluoroacetic acid. The samples were analyzed using a UPLC-nanoESI MS/MS setup 
with a NanoRSLC system (Dionex, CA, USA). The system was coupled online with an 
Objective PicoTip 360-20-10 emitter to a Q Exactive HF mass spectrometer (Thermo Scientific, 
Waltham, USA). All samples were analyzed in random order, in triplicates. Peptides were loaded 
onto a 2cm C18 trapping column (Dionex Acclaim PepMap RSLC C18) and separation was 
performed on a 75cm C18 reversed-phase column (Dionex Acclaim PepMap RSLC C18). Both 
were kept at 60°C. The peptides were eluted with a gradient of 98% solvent A (0.1% FA) and 
2% solvent B (0.1% FA in acetonitrile) at a constant flow rate of 300nL/min. Solvent B was 
increased to 8% on a 5-min ramp gradient and to 30% on a 45-min ramp gradient. The mass 
spectrometer was operated in positive mode using a Top15 data-dependent MS/MS scan method. 
A full MS scan in the 375-1500 m/z range was acquired at a resolution of 120 000 with an AGC 
target of 3×106 and a maximum injection time of 50ms. Fragmentation of precursor ions was 
performed by higher-energy C-trap dissociation with a normalized collision energy of 27. 
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MS/MS scans were acquired at a resolution of 15000 with an AGC target of 2×105; maximum 
injection time was 100ms. Dynamic exclusion was set to 5s. 
Data analysis 
Mass spectrometry raw files were analyzed in MaxQuant version 1.6.0.1 and searched 
against the Uniprot human reference FASTA database (August 2017, containing 70,941 protein 
groups). Label-free protein quantitation (LFQ) algorithm was performed with a minimum ratio 
count of 1. Standard settings in MaxQuant were applied. A maximum of two tryptic missed 
cleavages was allowed. The false discovery rate (FDR) of identified proteins and peptides was 
set to a maximum of 1%, using a target-decoy fragment spectra search strategy. High confidence 
identifications were ensured. The “match between runs” feature was activated to transfer peptide 
identifications from one run to another, based on accurate retention time and mass. 
Data processing 
The output from MaxQuant was further filtered and processed in Perseus version 1.6.0.2. 
All reverse database hits and proteins identified only by site were removed. To ensure high 
quality quantitative data, additional filtering was performed for the 1% FDR filtered data: at least 
two unique peptides were required for a protein quantitation; the unique peptides were required 
to be quantifiable in at least 70% of samples. A principle component analysis was performed in 
MATLAB (R2018a) software to investigate replicate outliers. Missing values were imputed with 
values from normal distribution (width 0.3 and downshift 1.8) to simulate signals from low 
abundant proteins, using standard parameters in Perseus [21]. There were no replicate outliers. 
Triplicate measurements of each sample were averaged in Perseus, and they were 
grouped according to timepoints: 16 samples pre-surgery, 16 at T1 and 9 at T2. Proteins with a 
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statistically significant abundance difference at any two timepoints were identified, using paired 
two sample t-test. To correct for multiple hypothesis testing, we applied permutation-based FDR 
control in Perseus using standard parameters (FDR:0.05, s0=0.1 and 250 randomizations). 
Bioinformatics analysis 
Differentially regulated proteins were functionally categorized based on gene ontology 
(GO) classification using WEB-based GEne SeT AnaLysis Toolkit (WebGestalt) [22]. 
Identification of canonical pathways and relevant networks was performed with Ingenuity 
Pathway Analysis software (IPA; Ingenuity Systems, Redwood City, CA, www.ingenuity.com). 
Gene symbols and the corresponding protein fold change were imported to IPA software using 
core analysis. Standard settings for core analysis were employed, including: direct and indirect 
relationships between focused molecules, based on experimentally observed data (high 
confidence predictions and moderate confidence interactions excluded) were considered. Default 
settings of 35 molecules/network were employed. All sources of data from human, mouse and rat 
studies in the Ingenuity Knowledge Base were included. Because the serum proteome represents 
a sub-proteome, which in itself contains enriched categories, all identified proteins were used as 
background for GO and IPA. In addition to user dataset (all identified proteins), the ingenuity 
Knowledge Base (genes only) was utilized as a reference set to match proteins in our dataset 
with those in the Ingenuity Knowledge Base. Right-tailed Fisher’s exact test was used to 
determine statistically significant pathways (p-value≤0.05). The mass spectrometry proteomics 
data have been deposited to the ProteomeXchange Consortium 
(http://proteomecentral.proteomexchange.org) via the PRIDE partner repository [23] with the 
dataset identifier PXD010528 
Validation of C-Reactive Protein and cytokine biomarkers quantitation 
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CRP and a number of cytokine biomarkers were further investigated with the Meso Scale 
Discovery (MSD) platform according to manufacturer's instructions. V-PLEX human CRP kit 
(MSD, Gaithersburg, USA) to measure CRP absolute concentration and proinflammatory panel 1 
human kit (MSD, Gaithersburg, USA) to measure some cytokines, including IL-6, IL-8, IL-10, 
IFN-γ, and TNF-α were used. All standards and samples were measured in duplicate. MESO 
QuickPlex SQ 120 instrument was used to read the plates and data analysis was carried out using 
the MSD Discovery Workbench software. 
Results 
Study Cohort 
A total of 16 obese subjects who underwent LGP, with the mean preoperative BMI of 
41.2±5.3 kg/m2 (33.1-48.5) and mean age of 37.9±10.2 years (22-48), was investigated to reveal 
the biological impact of weight loss due to LGP on human serum proteome. Subjects’ 
characteristics are shown in Table 1. It should be noted that because of geographical relocation 
of seven patients and their unavailability at T2, they were excluded from the study at that time 
point. However, baseline characteristics of subjects at T1 and T2 were not significantly different. 
At T1, mean BMI decreased significantly from 41.2±5.3 to 36.6±4.9 kg/m2 representing a 27% 
excess weight loss (EWL). The mean BMI measured at T2 was 32.5±5.4, with a 53.6% EWL.  
Proteomics data overview 
Protein digestion was performed on samples depleted of highly abundant proteins, using 
filter-aided sample preparation protocol. Randomized mass spectrometric data recorded in 
technical triplicate were subjected to protein identification and label free quantification. The 
workflow allowed us to identify 288 proteins. Following stringent filtering of the identified 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
12 
 
proteins to ensure only proteins with high quality quantification were retained, 224 proteins met 
our quantitation criteria (Supplementary Table 1 in Ref [24]). 
Quality control of proteomics data and cytokine biomarkers quantitation 
As a quality control of proteomics data, CRP was chosen for further investigation. 
Absolute quantitative CRP levels in all of the pre- and post-surgery samples were measured 
using MSD assay. Box plot diagrams of CRP concentration in paired samples and correlation 
analysis considering all samples are shown in Fig. 1. Log2 fold change of CRP in MSD assay 
measurement was found to be -1.8 at T1 and -2.2 at T2 which has a similar pattern compared 
with LFQ measurement (-2.2 and -2.6 at T1 and T2, respectively). As indicated in Fig. 1B, a 
strong positive correlation between MSD assay and LFQ measurement was observed (R=0.975 
and p-value=1.7e-26). The difference in CRP concentration between pre- and post-surgery 
samples, measured by both methods, is represented in Supplementary Fig. S1A. 
A number of cytokines that are important in inflammation and immune response 
regulation were measured in five randomly selected samples. There was a significant reduction 
(p-value<0.05) in the level of IL-6 at T1 and T2 versus pre-surgery and significant increase (p-
value<0.05) in the level of IL-8, IL-10, TNF-α, and INF-δ at T1 (Supplementary Fig. S1B-F). 
Proteins with a Timepoint-specific abundance 
Of the 224 quantifiable proteins, 48 (21.4%) had a statistically significant change in 
abundance (multiple testing correction by permutation-based FDR, FDR<0.05 and s0=0.1) at T1 
compared with pre-surgery subjects: 23 proteins were less abundant and 25 were more abundant 
(Fig. 2A, Table 2). For T2, seven proteins were measured having an altered abundance: four 
upregulated and three downregulated (Fig. 2B, Table 2). Six proteins including SHBG, ITIH3, 
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NRP1, IL1RAP, PRG4 and CRP were identified as regulated at both timepoints of post-surgery 
and only one protein, FN1, was exclusively found at T2. 
GO enrichment, Pathway and Network analysis 
Gene ontology (GO) overrepresentation analysis for biological process and molecular 
function was conducted with WebGestalt to gain a biological view of significantly changing 
proteins [22]. The complete list of enriched GO terms is reported in Table 2 and Table 3 for T1 
and T2 in Ref [24], respectively. The GO analysis revealed that most of the significantly 
changing proteins at T1 post-surgery have molecular functions such as lipid transporter activity, 
steroid binding and lipid binding. These proteins are enriched in biological processes related to 
protein and carbohydrate metabolism, whereas processes in the nervous system are mostly 
involved at T2. 
To identify pathways and networks of interacting proteins, significant differentially 
abundant proteins with the corresponding fold changes were investigated using protein network 
information within IPA. To estimate the correlation of the network with the original list of focus 
proteins, a score based on IPA algorithms is determined, which considers the number of focus 
proteins and the size of the network [25]. Five significant networks were identified when pre-
surgery subjects were compared with T1. The top enriched network defined as “Lipid 
Metabolism, Molecular Transport, Small Molecule Biochemistry” with a score of 45, containing 
18 differentially abundant proteins, is shown in Fig. 3A. Comparison of pre-surgery subjects 
with T2 showed a single protein-protein interaction network (Fig. 3B), containing seven focus 
molecules with a score of 21, which are related to “Cell-To-Cell Signaling and Interaction, Cell 
Death and Survival, Inflammatory Response”. Direct and indirect molecular interactions are 
indicated by solid and dashed lines, respectively. Nodes in yellow correspond with upregulated 
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proteins and those represented in blue are downregulated. Nodes shown in gray are in our dataset 
but no significant differences in abundance were observed. Colorless nodes are suggested by IPA 
due to their relation with enriched proteins. Details of networks components are presented in 
Table 4 in Ref [24].  
IPA was also used to connect significantly changing proteins to biological pathways. 
Firstly, we defined our identified proteins as a reference set. This revealed that alteration in the 
serum proteome at T1 correlates with alteration in eight enriched canonical pathways (p-
value<0.05) (Fig. 3C). IPA analysis of differentially regulated proteins at T2 resulted in 11 
enriched canonical pathways mainly involved in inflammation and the immune system (Fig. 3D). 
Left Y-axis shows –log of the P-value associated with each pathway, calculated by right-tailed 
Fischer’s exact test. The orange line represents a threshold of 0.05. The right Y-axis depicts the 
ratio of the number of proteins in our dataset that are connected to the pathway over the total 
number of proteins in that pathway. Differentially regulated proteins associated with each 
pathway with their information are reported in Supplementary Table S1. Secondly, the Ingenuity 
Knowledge Base (Genes Only) was defined as a reference set to determine pathways; the 
obtained enriched pathways are shown in Supplementary Fig. S2A and S2B. 
The Activation state of the pathways was predicted using Z-score. Positive Z-score 
values predict activation (orange bar), whereas a negative value indicates an inactivation or 
downregulation of an activity (blue bar). According to Z-score, predicted activity of 
PPARα/RXRα activation and LXR/RXR activation decreased at T1. 
Discussion 
The impact of LGP on weight loss and metabolic effects, such as improvement in 
diabetes and hypertriglyceridemia, have been investigated in the previous studies [17-18, 26]. 
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Moreover, changes in some gastrointestinal hormones including ghrelin, GIP and GLP-1 have 
been previously evaluated [12, 27-28]. In the present research, untargeted proteomic approach 
was used to investigate unanticipated changes in serum protein profile following LGP. In a large 
cohort of subjects (800 cases), it has been shown that patients experience 60% EWL at 6 months 
after LGP [17], along with improved body composition due to accelerated reduction of fat mass 
[11]. Given that rapid weight loss will occur during the first months following surgery, we set up 
two timepoints during the first 6 months post-surgery. 
Although LGP preserves the stomach fundus and does not include resection of secretory 
portions, we speculated that the reason for favorable effects of LGP, like other restrictive 
bariatric procedures, goes beyond the reduced volume of the stomach. Hence, it was expected 
that the effect of surgery would be reflected in the serum proteome, and the proteins would 
change by weight loss and the procedure. 
We demonstrated for the first time that LGP, as a new and not well studied procedure, 
has a comprehensive systemic impact which, upon comparison with other studies, goes beyond 
impacts of calorie restriction. Quantitation of CRP by electrochemiluminescent immunoassay 
using MSD platform was performed as a quality control and indicative marker of the 
inflammation related proteomics data. CRP was found to be significantly changed following 
surgery, and is known that BMI has a significant contribution in the levels of circulating CRP, 
which is a marker of elevated adiposity [29]. Consistent with the mass spectrometry results, 
MSD assay showed a significant reduction in CRP levels for post-surgery subjects versus pre-
surgery. As is clear from Fig. 1A, CRP, known as an inflammatory and risk marker for 
cardiovascular disease, is decreasing further at T2. We found a lower number of significantly 
changed proteins at T2 compared with T1. We ascribe this difference to be caused by i) many 
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serum-proteins having been returned to “normal” concentrations following surgical trauma and 
ii) seven pre-surgery subjects not being available at T2 and being excluded from analysis. Hence, 
the study has a reduced statistical power at T2.  
The sparse nature of the surgical procedure limited the number of samples we could 
obtain for the study. Nonetheless, we evaluated whether T1 collection time, gender, and age had 
an impact on the findings. The results showed that when T1 is divided into 1 and 2 months, 
females and males, and age groups, a smaller number of significant proteins will be detected, but 
the overall significant proteins are roughly the same and did not change (Supplementary Table 
S2). However, based on the present study, we cannot exclude that there is a co-factor impact on 
the study. Oller Moreno et al. [30] has reported that males and females have different molecular 
responses to the diet-induced weight loss. In the present study, we were not able to detect such 
an impact, but given the uniqueness of the samples and therefore limited number of samples, we 
cannot exclude that the same is true for LGP. 
Based on GO-analysis, most of the significantly changing proteins are involved in lipid- 
and carbohydrate metabolism. The two highest scoring networks, and hence the most affected 
networks by the procedure, identified using IPA at T1, network 1 and network 2, contained 
proteins involved in lipid metabolism and cardiovascular system development and function, 
respectively. It has been reported that RYGB has a significant role in improving cardiovascular 
functions which is mainly attributed to alterations in bile acid signaling, absorption and function 
[31]. It is worth noting that secretory regions of stomach are preserved in LGP, yet the procedure 
has a vast systemic impact with beneficial effects comparable with other surgeries. Among 
enriched pathways, PPARα/RXR α, LXR/RXR and FXR/RXR activation are most interesting 
and biologically relevant. LXRs, PPARs and FXRs are nuclear receptors with functions in lipid 
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and carbohydrate metabolism, as well as regulating bile acid and inflammatory response [32-34]. 
The specific mechanism by which these nuclear receptors contribute to glucose and lipid 
regulation by LGP should be investigated further.  
IL-6 signaling was identified as one of the pathways at both timepoints. IL-6 was not 
identified in our proteomics study. Therefore, we investigated IL-6 levels in serum samples using 
the MSD-assay to ascertain whether it changed or not, and IL-6 was significantly reduced at both 
timepoints after surgery (p-value<0.05). 
Differentially regulated proteins 
Most of the differentially regulated proteins had been described in the context of weight 
loss due to diet and/or bariatric surgery and BMI (Table 3). For instance, Neurophilin-1 (NRP1) 
was found to be significantly upregulated at both timepoints postoperatively. Similarly, Geyer et 
al. reported a significant increase in NRP1 levels after diet-induced weight loss [35]. Our report 
is the first to link NRP1 with weight loss following bariatric surgery. Interestingly, it has been 
reported very recently that NRP1, as expressed by macrophages, has a vital role in limiting 
obesity-associated inflammation and regulating fatty acid uptake in macrophages [36]. Reduction 
in the level of inflammatory markers such as CRP [35, 37] and SAA1[35, 38], and anti-
inflammatory markers increment such as ADIPOQ [39-40], IL1RAP [35, 41] and CD14 [35], 
which all are in accordance with previous findings are shown in Table 3. The link between 
obesity and metabolic syndrome has been attributed to the inflammatory process [42], and 
bariatric surgery is known to be effective in reduction of obesity-associated inflammation [37]. 
In addition to ADIPOQ, significant changes in the level of three other adipokines including 
RBP4, SRGN and SERPINF1 have been detected in our untargeted MS-based shotgun 
proteomics shown in Table 3. Moreover, significant reduction in pro-inflammatory IL-6 cytokine 
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at T1 and T2 and significant increase in anti-inflammatory IL-10 cytokine at T1 have been 
determined by MSD immunoassay. Modification in the level of these inflammatory and anti-
inflammatory markers may reflect improvement in the low-grade inflammation associated with 
obesity and can be attributed to the improvement in metabolic syndrome following LGP. 
In addition to the proteins known to be affected by weight loss, among the 48 proteins 
showing differential regulation at T1, 11 serum proteins had not previously been put into context 
with BMI, bariatric surgery or weight loss. As mentioned, we expected the serum proteins to be 
altered due to i) the weight loss/change in BMI, and ii) the surgery trauma which is especially 
present at T1. Of the 11 proteins, four proteins (SRGN, FETUB, LCP1, and CFP) appear to be 
changed by weight loss and BMI, while the rest showed alteration due to surgery, based on 
protein functions and previous reports. 
SRGN showed a significant increase postoperatively and is a new adipocytokine, highly 
expressed in adipocytes of epicardial adipose tissue. It is not yet clear what cell type and tissue 
account for circulating SRGN. It is proposed to be systemically involved in adipose tissue 
inflammation [43]. FETUB has been described as an adipokine/hepatokine which is increased in 
patients with insulin resistance/diabetes [44]. In a recent study comparing plasma protein profile 
of two obese cohorts from Canada and European countries, FETUB was identified as a gender-
associated protein [45]. It showed a significant reduction following LGP. LCP, with a role in the 
regulation of leukocyte adhesion, is hypothesized to correlate with body mass gain based on a 
study of mice on a high fat diet [46]. We found a significant increase in its circulating level 
postoperatively. CFP has been described as being involved in the alternative complement 
activation. CFP also contributes to altered lipid metabolism, insulin resistance and low grade 
inflammation [47]. We observed its reduction postoperatively. 
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The amount and speed of weight reduction following LGP, is much higher than the diet-
induced weight loss. Moreover, patients experience improvement in diabetes and glucose 
homeostasis following LGP, before occurring a significant weight reduction. Hence, the reason 
for accelerated weight loss and improvement in metabolic parameters are not only due to the 
gastric volume reduction; in fact, underling mechanism in LGP could be different from the diet-
induced weight loss. According to the findings, most of the regulated proteins are shared 
between LGP and dietary intervention. This shows that LGP does not result in unusual impacts 
on the global serum proteome and it can be safe regarding the dynamic changes in the serum 
proteome. On the other hand, these regulated proteins, except nine proteins in overall 49 
significant proteins, also have found following weight loss by other types of bariatric surgeries 
(Table 3).  
Recent study by Albrechtsen et al. [48], investigating dynamics of plasma proteome after 
RYGB revealed changes in inflammatory and lipid homeostasis markers. This study compared 
with the research on the caloric restriction (Cambridge diet) carried out by the same group [35] 
showed a significant overlap of inflammatory proteins. By contrast, a differently regulated lipid 
homeostasis system was identified between two interventions. 
In our research, some of the proteins in the inflammatory panel identified by the above-
mentioned group including CRP, CD14, CFI, C7, CFI, C4BPA, FN1, SAA1, and SERPINF2 
were found. Based on the results carried out by that group, LDL-associated proteins have been 
regulated in a similar direction in both interventions, while HDL-associated proteins such as 
APOA1, APOA2, APOA4 and APOM were only increased after RYGB. Contrary to the 
mentioned group’s results, we found reduction in the level of these apolipoproteins. We 
attributed this inconsistency to the time of study, as they found the increase after 52 and 104 
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weeks following surgery. In another study which inspected the difference between gastric bypass 
and low-calorie diet [49], pathway analysis revealed that regulated proteins influence 
inflammation and lipid metabolism in both interventions, while carbohydrate and protein 
metabolism have been affected in surgery intervention. These results are in line with our findings 
from pathway and network analysis after LGP. 
Exclusively identified protein at timepoint T2 
FN1 was the only protein with a statistically significant reduction identified exclusively 
at T2. It has been shown that FN1 is one of the dysregulated adipocyte-specific genes in obese 
adipose tissue and its plasma level has a positive correlation with BMI and triglyceride 
concentration in overweight subjects [50-51]. For the first time, we have found its connection to 
surgery-induced weight loss with an expected reduction in its levels. 
Proteins with opposite regulation pattern compared with known protein changes 
We found eight proteins whose directionality of abundance differences were in contrast 
with previous reports. The levels of THBS1, SPARC, VWF, and C4BPA were significantly 
increased at T1. THBS1 plays a role in proinflammatory adipokines production. Its serum level 
is correlated with the degree of obesity and has been found to be decreased one year after 
laparoscopic sleeve gastrectomy [52]. SPARC, as the first extracellular matrix protein described 
in adipose tissue, was reported to have been significantly reduced after 9 months of RYGB [53]. 
The observed difference of these two proteins might be due to the time of the study. Long-term 
follow up is required to indicate the reason for this inconsistency. VWF, as a marker of 
endothelial dysfunction, was reported to be significantly downregulated after RYGB [54]. The 
effect of bariatric surgery on the markers of endothelial function was described in the literature 
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[55]. It has been proposed recently that the weight loss is not the only reason for endothelial 
function improvement; other effects of RYGB may be involved [54]. More studies are required 
to further explore the VWF changes following bariatric surgeries. C4BPA, which is known as an 
inhibitor of classical and lectin complement pathways, can bind to CRP and decrease the 
complement activation [56]. In a recent study investigating the plasma proteome changes after 
RYGB, the levels of C4BPA have been significantly reduced [48]. In contrast to our study, the 
levels of CRTAC1, APOA1, APOA2, and APOA4 have been significantly increased in the 
recent mentioned study [48]. We attributed this inconsistency to the time of study, as they found 
the increase at the first weeks following surgery (2 weeks) or after 52 and 104 weeks. 
Of note, RYGB and LSG are associated with dramatic anatomical and physiological 
changes. For that reason, it is possible that the above-mentioned opposite changes are as a result 
of the type of surgery.  
Conclusions 
We present the first study that provides a broader insight into the dynamic changes in the 
serum proteome indicative of systemic low-grade inflammation reduction due to LGP-induced 
weight loss. The vast systemic impact of LGP, based on the blood serum proteome profile, 
supports the hypothesis that food restriction is not the only reason for weight loss following 
LGP, and it might account for accelerated reduction of fat mass. 
It is an interesting finding since LGP preserves the secretory regions of the stomach and 
is associated with minimal physiologic changes in the gastrointestinal tract. A panel of 
significantly altered proteins were reported in previous studies and four novel affected proteins 
in the context of BMI/weight loss, including SRGN, FETUB, LCP1 and CFP, have been found. 
Based on pathway and Go analysis results, LGP has the potential to change proteins involved in 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
22 
 
lipid metabolism, inflammation and carbohydrate metabolism. Of importance, our findings 
contribute to existing weight loss proteomic studies and, in addition, may explain that reported 
metabolic improvement after LGP may occur from a similar mechanism to other weight loss 
strategies. However, bearing in mind the small sample size as a limitation of our research that 
may make the study as a hypothesis-generating pilot study, we suggest further research with 
larger populations and evaluate any possible co-factor effects such as gender dependency and 
also comparing different surgical approaches. This will lead to in-depth understanding of 
possible differences in surgically induced weight loss effects on human blood proteome and 
associated mechanism. 
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Figure legend 
Fig. 1. (A) Box plot of CRP concentration in paired samples according to proteomics LFQ 
intensity and MSD assay. P-values calculated by paired two-sample t-tests. (B) Correlation 
analysis between proteomics and MSD assay measurement. Pearson correlation and p-value are 
shown.  
Fig. 2. (A) Volcano plots of protein changes comparing T1 and pre-surgery, and (B) T2 and pre-
surgery. Each dot depicts a quantified protein, and the statistically significant proteins have been 
highlighted in red. The black curve represents the threshold of significance of FDR < 0.05 after 
applying permutation-based FDR control at s0=0.1. 
Fig.3. (A) The top-scoring network when pre-surgery subjects were compared with T1, and (B) 
The only identified network when pre-surgery subjects were compared to T2. Direct and indirect 
molecular interactions are indicated by solid and dashed lines, respectively. Nodes in yellow 
correspond with upregulated proteins and those represented in blue are downregulated. Nodes 
shown in gray are in our dataset but no significant differences in abundance were observed. 
Colorless nodes are suggested by IPA due to their relation with enriched proteins C) Canonical 
pathways affected by differentially regulated proteins at T1, and (D) T2. Left Y-axis shows –log 
of the P-value associated with each pathway, calculated by right-tailed Fischer’s exact test. The 
orange line represents a threshold of 0.05. The right Y-axis depicts the ratio of the number of 
proteins in our dataset that are connected to the pathway over the total number of proteins in that 
pathway. 
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Table 1. Clinical and demographic characteristics of study subject 
Variable Pre-surgery 
(n=16) 
T1 
(n=16) 
T2 
(n=9) 
p-value 
pre vs 
T1 
p-value 
pre vs 
T2 
Age (years) 37.9 ± 10.2 - 36.9 ± 11.9 - - 
Gender ratio, (F:M) 11:5 11:5 6:3 - - 
BMI (Kg/m2) 41.2 ± 5.3 36.6 ± 4.9 32.5 ± 5.4 <0.0001 <0.0001 
%EWL - 27 ± 6.3% 53.6 ± 15% - - 
Triglycerides (mg/dl) 130.63 ±  
53.78 
106.88 ± 
40.98 
91.89 ±  
24.7 
<0.05                   <0.05
Cholesterol (mg/dl) 176.69 ±  
36.20 
166.38 ± 
28.77 
165.89 ±  
30.25 
 
NS NS 
HDL-C (mg/dl) 45.5 ±  
12.44 
 
39.31 ± 
8.38 
 
46.67 ±  
7.31 
 
<0.05                   NS
LDL-C (mg/dl) 105.23 ±  
27.03 
 
105.25 ±  
23.93 
 
101 ±  
27.34 
 
NS NS 
Base-line comorbidity 
Hypertension 
Dyslipidemia 
Depression 
 
3 (18.7%) 
  8 (50%) 
3 (18.7%) 
- - - - 
 
Values are mean ± standard deviation, or the number of subjects  
 p-values are presented using paired-t test  
 BMI body mass index, LDL-C low-density lipoprotein cholesterol, HDL-C high-density 
lipoprotein Cholesterol, NS Not Significant, EWL% percent excess weight loss  
EWL%= (preoperative weight – weight at each visit/excess weight × 100%) 
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Table 2. Significantly changed serum proteins (q-value <0.05) post- vs pre-surgery 
 
Protein IDs Protein names Gene names 
-log 10 p-
value 
Fold change log2 
(post vs pre) 
T1 vs pre-surgery 
P04278 Sex hormone-binding globulin SHBG 8.75 1.16 
P10124 Serglycin SRGN 2.58 1.10 
P20742 Pregnancy zone protein PZP 1.71 1.06 
Q06033 
Inter-alpha-trypsin inhibitor heavy 
chain H3 
ITIH3 8.76 0.87 
Q15848 Adiponectin ADIPOQ 1.78 0.81 
Q13790 Apolipoprotein F APOF 7.89 0.80 
O14786 Neuropilin-1 NRP1 6.65 0.74 
P05090 Apolipoprotein D APOD 2.35 0.67 
P04003 C4b-binding protein alpha chain C4BPA 1.75 0.61 
P13796 Plastin-2 LCP1 5.50 0.59 
Q9NPH3 
Interleukin-1 receptor accessory 
protein 
IL1RAP 4.45 0.57 
P16930 Fumarylacetoacetase FAH 2.03 0.54 
P09172 Dopamine beta-hydroxylase DBH 1.61 0.54 
Q13201 Multimerin-1 MMRN1 3.64 0.47 
Q14126 Desmoglein-2 DSG2 4.01 0.46 
O95445 Apolipoprotein M APOM 6.03 0.44 
P07359 Platelet glycoprotein Ib alpha chain GP1BA 3.62 0.38 
P04275 
von Willebrand factor;von 
Willebrand antigen 2 
VWF 2.01 0.36 
P08697 Alpha-2-antiplasmin SERPINF2 2.06 0.36 
P12955 Xaa-Pro dipeptidase PEPD 2.30 0.33 
P19823 
Inter-alpha-trypsin inhibitor heavy 
chain H2 
ITIH2 4.27 0.31 
P08571 
Monocyte differentiation antigen 
CD14 
CD14 4.67 0.31 
P07996 Thrombospondin-1 THBS1 2.77 0.28 
P09486 SPARC SPARC 3.73 0.27 
P10643 Complement component C7 C7 5.27 0.216 
Q99969 
Retinoic acid receptor responder 
protein 2 
RARRES2 3.93 -0.30 
P02647 Apolipoprotein A-I APOA1 2.82 -0.31 
P05156 Complement factor I CFI 5.994 -0.32 
P00742 Coagulation factor X F10 3.77 -0.32 
P02766 Transthyretin TTR 5.48 -0.36 
P02652 Apolipoprotein A-II APOA2 2.87 -0.38 
P02753 Retinol-binding protein 4 RBP4 3.37 -0.38 
P08709 Coagulagction factor VII F7 3.32 -0.39 
P36955 Pigment epithelium-derived factor SERPINF1 4.94 -0.39 
P80108 
Phosphatidylinositol-glycan-specific 
phospholipase D 
GPLD1 5.12 -0.46 
Q6UXB8 Peptidase inhibitor 16 PI16 1.81 -0.52 
P27918 Properdin CFP 6.12 -0.53 
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P14780 Matrix metalloproteinase-9 MMP9 1.46 -0.62 
P02774 Vitamin D-binding protein GC 1.66 -0.63 
Q92954 Proteoglycan 4 PRG4 7.12 -0.707 
P06727 Apolipoprotein A-IV APOA4 2.52 -0.71 
Q96KN2 Beta-Ala-His dipeptidase CNDP1 6.53 -0.78 
Q9UGM5 Fetuin-B FETUB 5.67 -0.789 
P02743 Serum amyloid P-component APCS 3.04 -0.85 
Q9NQ79 Cartilage acidic protein 1 CRTAC1 1.76 -1.06 
P02741 C-reactive protein CRP 1.76 -1.08 
P0DJI8 Serum amyloid A-1 protein SAA1 2.46 -1.391 
P68871 Hemoglobin subunit beta HBB 5.22 -1.45 
T2 vs pre-surgery 
Q92954 Proteoglycan 4 PRG4 3.69 -0.83 
O14786 Neuropilin-1 NRP1 2.89 0.68 
P04278 Sex hormone-binding globulin SHBG 3.80 0.96 
P02741 C-reactive protein CRP 2.85 -2.6 
P02751 Fibronectin FN1 3.06 -0.70 
Q06033 
Inter-alpha-trypsin inhibitor heavy 
chain H3 
ITIH3 4.95 0.82 
Q9NPH3 
Interleukin-1 receptor accessory 
protein 
IL1RAP 2.92 0.59 
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Table 3. Significantly altered abundance proteins compared to literature 
 
Gen names Direction of change in our 
study 
Previously reported 
Direction of change/ Context Reference 
SHBG  / Diet- and surgery-induced weight loss 
(RYGB and SG) 
[30, 35, 48, 
57] 
SRGN  - - 
PZP  / Diet-induced weight loss [58] 
ITIH3  /  Diet- and surgery-induced weight loss 
(RYGB) 
[30, 35, 48] 
ADIPOQ  / Diet- and surgery-induced weight loss 
(RYGB) 
[30, 39-40, 
48] 
APOF  / Diet-induced weight loss [35] 
NRP1  / Diet-induced weight loss [35] 
APOD  / surgery-induced weight loss (RYGB) [48, 59] 
C4BPA  / surgery-induced weight loss (RYGB) [48] 
LCP1  - - 
IL1RAP  / Diet- and surgery-induced weight loss 
(RYGB) 
[35, 41] 
FAH  - - 
DBH  / Diet-induced weight loss [30] 
MMRN1  - - 
DSG2  - - 
APOM  / Surgery-induced weight loss (RYGB) [48] 
GP1BA  / Diet-induced weight loss [35] 
VWF  / Diet- and surgery-induced weight loss 
(RYGB) 
[54, 60] 
SERPINF2  / Diet-induced weight loss [35] 
PEPD  - - 
ITIH2  / Diet-induced weight loss [30, 35] 
CD14  / Diet-induced weight loss [35] 
THBS1  / Surgery-induced weight loss (SG) [52] 
SPARC  / Surgery-induced weight loss (RYGB) [53] 
C7  /  Diet- and surgery-induced weight loss 
(RYGB)  
[30, 35, 48] 
RARRES2  / Diet- and surgery-induced weight loss 
(RYGB, SG) 
[61-62]  
APOA1  / Diet-induced weight loss 
/Surgery-induced weight loss (RYGB) 
[35, 48] 
CFI  /  Diet- and surgery-induced weight loss 
(RYGB) 
[30, 35, 48] 
F10  /  Diet- and surgery-induced weight loss 
(RYGB) 
[48, 63-64] 
TTR  / Diet- and surgery-induced weight loss 
(RYGB, SG) 
[35, 48, 65] 
APOA2  /  Diet- induced weight loss /Surgery-
induced weight loss (RYGB) 
[35, 48] 
F7  - - 
RBP4  / Diet- and surgery induced weight loss 
(gastric banding, RYGB) 
[35, 48, 66] 
SERPINF1  / Diet- and surgery-induced weight loss [35, 48, 67] 
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(SG, RYGB) 
GPLD1  /  Diet- and surgery-induced weight loss 
(RYGB) 
[35, 48] 
PI16  - - 
CFP  - - 
MMP9  / Surgery-induced weight loss (gastric 
banding) 
[68] 
GC  / Surgery-induced weight loss (SG) [67] 
PRG4  / Diet- and surgery induced weight loss 
(RYGB, SG) 
[35, 48, 69]  
APOA4  /Diet- and surgery-induced weight loss 
(SG, RYGB) 
/surgery-induced weight loss (RYGB) 
[35, 48, 70-
71]  
CNDP1  /  Diet- and surgery-induced weight loss 
(RYGB) 
[35, 48] 
FETUB  - - 
APCS  /  Diet- and surgery-induced weight loss 
(RYGB) 
[35, 48] 
CRTAC1  / Surgery-induced weight loss (RYGB) [48] 
CRP  / Diet- and surgery-induced (SG, 
RYGB and gastric banding) 
[35, 37, 48] 
SAA1  / Diet- and surgery-induced weight loss 
(RYGB) 
[35, 38, 48] 
HBB  - - 
FN1  / Diet-induced weight loss [35] 
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Significance 
Among the available clinical therapies for morbid obesity, bariatric surgery is considered as the 
most effective approach to achieve long-term weight loss, alongside a significant improvement 
in metabolic syndrome. However, very little is known about the underlying mechanism 
associated with significant weight loss post-surgery. Understanding such mechanisms could lead 
to development of safer non-surgical weight loss approaches. We here present the first analysis 
of the impact of LGP on the serum proteome, to bring new insights into the underlying molecular 
mechanism. Our findings indicate that LGP has a comprehensive systemic effect based on the 
blood serum proteome profile which might account for accelerated reduction of fat mass after 
surgery, thus, food restriction is not the only reason for weight loss following this unique 
surgical approach. As secretory regions of the stomach are preserved in LGP and it is associated 
with minimal physiological and anatomical changes, the findings are of high importance in the 
field of bariatric surgery and weight loss. 
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Highlights 
 The systemic impact of LGP on the global serum proteome was investigated. 
 A panel of significantly altered proteins including some novel proteins was detected.  
 LGP has the potential to change proteins involved in lipid metabolism and inflammation. 
 Food restriction is not the only reason for weight loss following LGP. 
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